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Background/Introduction: Osteopetrosis is a group of rare
genetic disorders characterized by increased bone density.
Osteopetrosis is genetically heterogeneous and nine causal genes
have been reported. Nevertheless, no mutation is found among these
reported genes on some patients, suggesting unknown causal genes
exist. Anion exchanger 2 (AE2, encoded by SLC4A2) exports
carbonate ions and imports chloride ions to maintain the
intracellular pH. AE2 is highly expressed in osteoclasts. SLC4A2-
deficient mice and cattle display osteopetrosis associated with
dysfunctional osteoclasts; however, no mutations in human SLC4A2
have been reported to date in the context of osteopetrosis.
Purpose: To identify SLC4A2-associated osteopetrosis in human.
Methods: Whole exome sequencing and Sanger sequencing were
used to detect the variant in the patient. Pathogenicity of the variants
was assessed by a gene knockout-rescue system using mouse
macrophage cell line, RAW 264.7.
Results: Bywhole exome sequencing, we identified novel compound
heterozygous variants in SLC4A2 (NM_003040.4: c.556GNA [p.A186T] and
c.1658TNC [p.V553A]) in an osteopetrosis patient. Osteoclast
differentiation induced by RANKL showed that osteoclastogenesis was
impaired in Slc4a2-knockout RAW 264.7 cells. The impairment was
rescued by wild-type SLC4A2, but not by mutant SLC4A2.
Conclusion(s): We discovered the first case of SLC4A2-associated
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Background/Introduction: XLH is a rare genetic condition which
affects phosphate metabolism, resulting in osteomalacia. Individuals
with XLH are also at risk of lower limb deformities and early onset of
hip osteoarthritis. These two factors may be linked, as abnormal FNA
(femoral torsion) is a risk factor for hip osteoarthritis. The
contributions of regional femoral torsion e.g. intertrochanteric
torsion (ITT), shaft torsion (ST) and condylar torsion(CT) to FNA
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differ between clinical groups and are important when planning
femoral osteotomies to correct FNA.
Purpose: This study aimed to compare FNA and regional femoral
torsion of the femur between adults with XLH and controls.
Methods: 13 individuals with XLH (5 male, age 49±9y) and 12 age,
sex and weight-matched control participants (7 male, age 49±8y) were
recruited following ethical approval and informed consent. Magnetic
resonance imaging (MRI) scans of the femur were obtained, from which
FNA, ITT, ST and CT were measured. Data were normally distributed,
therefore group differences were assessed using t-tests.
Results: FNA was 29° lower in individuals with XLH than controls
(pb0.005). This resulted mainly from lower ITT (pb0.001) and in part
CT (pb0.05) whereas ST was similar in the two groups (Fig. 1).
Conclusion(s): We observed differences in FNA and region-
specific femoral torsion in individuals with XLH compared to
controls. These differences may contribute to clinical problems such
as hip osteoarthritis common in XLH. Information on region-specific
differences may be useful in planning corrective surgeries. Future
work should examine how pharmacological and other interventions
in this group affect FNA.
doi:10.1016/j.bonr.2021.100785
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Background/Introduction: Osteogenesis imperfecta (OI) is a
hereditary disorder of the connective tissue with a heterogeneous
clinical presentation. A hallmark of OI is frequent fractures occurring
with little or no trauma. Pregnancy and lactation are periods of
increased fetal demand for calcium known to often result in an
asymptomatic and fully reversible decrease in maternal Bone
Mineral Density. Fracture risk associated with this bone loss among
women with OI has not yet been evaluated.
Purpose: To evaluate the fracture rates and risk in the short and
longer term associated with pregnancy.
Methods: Self-controlled case series 12- and 19- months prior to
conception compared to a period of 12- and 19 months, respectively,
postpartum among women with OI.The study is based on register
data from the Danish National Patient Register. All women registered
in the Danish National Patient Register with a WHO International
Classification of Diseases 8th or 10th edition code for OI who gave
birth one or more times in the period between 01.01.1995-
31.12.2018 and who had a 12 or 19 months pre- and postpartum
observation period were included.
Results: We found an incidence rate (IR) 12 months prior to
conception of 59.9 [95%CI 22.8-97] per 1000 person years and an IR
12 months postpartum of 29.9 [95%CI 3.7-56.18]. Comparing pre-
and post-pregnancy periods we found an incidence rate ratio (IRR) of
0.5 [95%CI 0.17-1.46]. Adjusting for parity and age at delivery did not
significantly change in IRR. For the 19 months window the IR per
1000 person years pre-pregnancy was 58.28 [95%CI 36.16-87.77] and
the IR postpartum 51.12 [95%CI 23.33-78.91], leading to an IRR of
0.87 [95%CI 0.40-1.82].
Conclusion(s): We found no evidence that the anticipated
physiological decline in BMD during pregnancy and lactation leads
to a higher risk of fractures in women with OI.
doi:10.1016/j.bonr.2021.100786
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Background/Introduction: Breast microcalcifications are
deposits of calcium oxalate, found mostly in benign tissue, or
calcium phosphate in the form of hydroxyapatite, found in benign
and malignant tissue. Differences in the crystallographic properties
and chemical make-up of hydroxyapatite breast microcalcifications
have previously been noted in differing breast pathologies.
Purpose: Ductal carcinoma in-situ (DCIS) is a precancerous breast
lesion, which has the potential to form invasive breast cancer.
Currently there are no definitive markers to determine DCIS
invasiveness, therefore this work aims to elucidate differences in
the calcification chemistry between invasive and non-invasive cases
of DCIS, ultimately developing a novel biomarker for DCIS
progression.
Methods: 75 formalin fixed paraffin embedded archive breast
tissue samples were used subject to NHS REC approval (ref. 18/LO/
0945). X-ray diffraction was carried out at 12keV on beamline i18 at
Diamond Light Source, UK to determine crystallographic properties
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